The wealth of potentially antigen-selective αβ and γδ TCRs recognizing CD1- or MR1-antigen complexes hold great therapeutic potential for cancer and infection-specific T cell therapy restricted by CD1 or MR1. This evidence concerns the gene MR1 and infection.